Abstract:In the last 20 years epidermal stem cells have been extensively used for tissue regeneration of epidermis and other epithelial surfaces. The tremendous progress achieved has led to the development of protocols aimed at the correction of rare genetic disorders such as epidermolysis bullosa (EB), a severe, often lethal, blistering disorder of the skin. Approximately 400,000 – 500,000 people are affected worldwide and no definitive treatments have yet been developed. Gene therapy might represent an alternative therapeutic approach. This paper reviews the different strategies used to genetically modify keratinocytes from EB patients and addresses issues such as the use of in vivo or ex vivo approaches, how to target keratinocytes with stem cell properties in order to have long-term therapeutic gene expression, and which gene transfer agents should be used. The progress made has led the authors' group to submit a request for a Phase I/II ex vivo therapy clinical trial for patients with junctional EB.

Gene therapy in combination with tissue engineering to treat epidermolysis bullosa / S., Ferrari; Pellegrini, Graziella; T., Matsui; Mavilio, Fulvio; DE LUCA, Michele. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - STAMPA. - 6:(2006), pp. 367-378.

Gene therapy in combination with tissue engineering to treat epidermolysis bullosa

PELLEGRINI, Graziella;MAVILIO, Fulvio;DE LUCA, Michele
2006

Abstract

Abstract:In the last 20 years epidermal stem cells have been extensively used for tissue regeneration of epidermis and other epithelial surfaces. The tremendous progress achieved has led to the development of protocols aimed at the correction of rare genetic disorders such as epidermolysis bullosa (EB), a severe, often lethal, blistering disorder of the skin. Approximately 400,000 – 500,000 people are affected worldwide and no definitive treatments have yet been developed. Gene therapy might represent an alternative therapeutic approach. This paper reviews the different strategies used to genetically modify keratinocytes from EB patients and addresses issues such as the use of in vivo or ex vivo approaches, how to target keratinocytes with stem cell properties in order to have long-term therapeutic gene expression, and which gene transfer agents should be used. The progress made has led the authors' group to submit a request for a Phase I/II ex vivo therapy clinical trial for patients with junctional EB.
6
367
378
Gene therapy in combination with tissue engineering to treat epidermolysis bullosa / S., Ferrari; Pellegrini, Graziella; T., Matsui; Mavilio, Fulvio; DE LUCA, Michele. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - STAMPA. - 6:(2006), pp. 367-378.
S., Ferrari; Pellegrini, Graziella; T., Matsui; Mavilio, Fulvio; DE LUCA, Michele
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/310553
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 24
social impact